



Press release Stockholm 2023-10-13 08:30 CET

Kancera announces that the FRACTAL top line results are expected to be presented by the end of December 2023

Kancera AB (publ) today announces that the top line results from the FRACTAL study are delayed. The company expects that results will be presented by the end of December 2023.

FRACTAL, a phase IIa study of Kancera's candidate drug KAND567 in patients with myocardial infarction undergoing percutaneous coronary intervention, is being conducted in collaboration with the Newcastle Hospitals NHS Foundation Trust (NHS), sponsor of the study.

As previously reported, Kancera and NHS have completed all analyses of data related to the primary and secondary endpoints and the study database has been validated and locked. Before top line results can be reported, statistical analysis and unblinding of data have to be completed, activities conducted by NHS.

Due to a lack of statistical resources within NHS to finalize these remaining activities, Kancera's presentation of the study results is delayed. Based on the current project status and available resources for the remaining activities, Kancera expects that top line results will be reported by the end of December this year, a delay with approximately two months vs previous expectation.

About the FRACTAL study

The FRACTAL study is an ongoing clinical phase IIa study of Kancera's fractalkine-blocking drug candidate KAND567 in myocardial infarction patients undergoing percutaneous coronary intervention. The study, a two-arm, double-blinded and placebo-controlled study, is conducted in collaboration with the NHS Foundation, sponsor of the study, at the two hospitals Freeman Hospital in Newcastle and James Cook Hospital in Middlesbrough. The primary objective is to evaluate safety and tolerability. The secondary objective is to evaluate signs of heart-protective effects.

About Kancera AB (publ)

Kancera is developing a new class of drugs for treatment of cancer and severe inflammatory diseases that currently lack effective treatments. Kancera's main focus is to develop small molecule drug candidates based on the fractalkine axis. The fractalkine axis is a natural master regulator that exerts precision controls on immune cells and cancer cells. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser.

For further information:

Peter Selin
Chief Executive Officer, Kancera AB
Phone: +46 (0)8-5012 60 80

Visit Kancera's web page: <https://www.kancera.com/en>

This information is information that Kancera is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-10-13 08:30 CEST.